Get the Stockscreener App
2.19
3.30%
0.07
After Hours:
2.21
0.02
+0.91%
Moleculin Biotech Inc stock is traded at $2.19, with a volume of 110.27K.
It is up +3.30% in the last 24 hours and down -33.03% over the past month.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
See More
Previous Close:
$2.12
Open:
$2.14
24h Volume:
110.27K
Relative Volume:
0.23
Market Cap:
$15.47M
Revenue:
-
Net Income/Loss:
$-30.33M
P/E Ratio:
-0.0781
EPS:
-28.0369
Net Cash Flow:
$-24.28M
1W Performance:
+2.34%
1M Performance:
-33.03%
6M Performance:
-51.55%
1Y Performance:
-84.55%
1-Day Range:
$2.09
$2.26
1-Week Range:
$2.04
$2.26
52-Week Range:
$1.79
$18.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.19 | 14.98M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin Biotech, Inc. Revenue Breakdown – NASDAQ:MBRX - TradingView
TradingKey - TradingKey
Enterprise value to EBIT forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
MBRX|Moleculin Biotech Inc|Price:2.120|Chg%:+0.040 - TradingKey
Moleculin Biotech Inc (MBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moleculin Biotech Inc (MBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Moleculin Biotech Inc (MBRX) Institutional Confidence - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.150|Chg%:+0.030 - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.160|Chg%:+0.040 - TradingKey
Moleculin Biotech Inc (MBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Moleculin Biotech Inc (MBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MBRX stock trades around recent lows as Moleculin focuses on cash runway and clinical progress - Ad-hoc-news.de
MBRX|Moleculin Biotech Inc|Price:2.100|Chg%:+0.020 - TradingKey
MBRX stock holds the line as Moleculin advances its pipeline - Ad-hoc-news.de
Moleculin Biotech Inc (MBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Enterprise value to revenue forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Price to sales forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Price to book forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Moleculin Biotech (MBRX) Weakens: Stock Drops 6.56% as Key Support Levels TestedTrend Reversal Picks - dars.gov.et
Enterprise value to EBITDA forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Price to earnings forward of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech focuses on oncology pipeline and Nasdaq listing - ad-hoc-news.de
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor 'What This Means' Segment - marketscreener.com
Moleculin CEO discusses preliminary results from leukemia trial By Investing.com - Investing.com Australia
Moleculin CEO discusses preliminary results from leukemia trial - Investing.com
Moleculin reports positive early results from P... - Pluang
Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment - Quiver Quantitative
Moleculin CEO, Walter Klemp, Highlights Positive - GlobeNewswire
Moleculin Biotech (MBRX) Shares Slide 9% as Stock Approaches Key Support LevelVolume Breakout Ideas - dars.gov.et
Moleculin Biotech | 8-K: Current report - Moomoo
MBRXMoleculin Biotech Inc Dividends - Finviz
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI
Why is Moleculin stock falling today? - MSN
Moleculin Biotech (MBRX) Plunges 25% as Key Support Nears—What’s Behind the Sharp DeclineATR Stop - dars.gov.et
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance - Asianet Newsable
Moleculin Biotech, Inc. Financial Disclosures & Filings - TradingView
Why is Moleculin Stock Falling Today? - Benzinga
H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Moleculin Biotech (MBRX) Reports Positive Efficacy Results in Ph - GuruFocus
Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data. - Bitget
Moleculin reports positive interim data from AML trial - Investing.com
Moleculin Biotech Updates Investors With New Presentation - TipRanks
Moleculin Biotech Reports Promising Annamycin AML Trial Data - TipRanks
Moleculin Biotech, Inc. Shares June 2026 Investor Presentation and Key Regulatory Updates - Minichart
Moleculin reports positive interim data from AML trial By Investing.com - Investing.com India
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control - The Manila Times
Form 8-K Moleculin Biotech, Inc. For: Jun 30 - StreetInsider
Annamycin boosts remission in Moleculin (MBRX) pivotal AML MIRACLE trial interim - Stock Titan
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):